KMDA Kamada Ltd.

6.02
+0.08  (+1%)
Previous Close 5.94
Open 6.01
Price To Book 2.16
Market Cap 242410513
Shares 40,267,527
Volume 101,948
Short Ratio
Av. Daily Volume 28,450

NewsSee all news

  1. Is Kamada (KMDA) a Great Value Stock Right Now?
  2. Kamada: 4Q Earnings Snapshot
  3. Kamada Reports Financial Results for Fourth Quarter and Fiscal Year 2018
  4. Kamada Announces Additional Interim Results from Phase 2 Proof of Concept Clinical Trial of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant Rejection
  5. Kamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2018 Financial Results and Host Conference Call on February 12

SEC filingsSee all SEC filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19603668
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19600492
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19600482
  4. 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 19587509
  5. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19573452

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data due 2H 2019.
Alpha-1 antitrypsin (AAT)
Prevention of lung transplant rejection
Approval announced August 25, 2017.
KamRAB
Prophylaxis of rabies disease
Top-line data released August 30, 2016. Primary endpoint met. Company noted April 23, 2018 safety concerns by FDA. Initiation of Phase 3 trial planned for 2019.
Inhaled formulation of AAT
AATD - Alpha-1 Antitrypsin deficiency
Phase 2 data released November 3, 2017. No significant treatment effect noted overall.
Alpha-1 Antitrypsin (AAT)
Pediatric patients newly diagnosed with type 1 diabetes
Phase 2 data due 2H 2019.
Alpha-1 antitrypsin (AAT)
Graft Versus Host Disease (GvHD)

Latest News

  1. Is Kamada (KMDA) a Great Value Stock Right Now?
  2. Kamada: 4Q Earnings Snapshot
  3. Kamada Reports Financial Results for Fourth Quarter and Fiscal Year 2018
  4. Kamada Announces Additional Interim Results from Phase 2 Proof of Concept Clinical Trial of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant Rejection
  5. Kamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2018 Financial Results and Host Conference Call on February 12
  6. Kamada Appoints Senior Biopharmaceutical Executive Michal Ayalon, Ph.D., as Vice President of Research and Development
  7. Kamada Announces Preliminary Revenue for Fourth Quarter and Full-Year 2018
  8. Kamada (KMDA) Reports Q3 Loss, Misses Revenue Estimates
  9. Cannabics Pharmaceuticals Inc. Appoints Dr. Estery Giloz-Ran to Its Advisory Board
  10. The Zacks Analyst Blog Highlights: American River, BG Staffing, Evolution Petroleum, Kamada and Farmers & Merchants
  11. Dollar Strengthens on Turkey's Trouble: Top 5 Gainers
  12. Kamada (KMDA) Surpasses Q2 Earnings and Revenue Estimates

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19603668
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19600492
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19600482
  4. 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 19587509
  5. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19573452
  6. 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 19569832
  7. 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 19566168
  8. 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 19550352
  9. 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 19500059
  10. 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 181244689